URGN UroGen Pharma Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1668243 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY159.3%
TTM net income YoY60.1%
TTM EPS YoY—
Revenue 3-yr CAGR47.9%
Net income 3-yr CAGR—
Margins
Gross margin91.4%
Operating margin-12.4%
Net margin-26.3%
FCF margin-52.8%
EBITDA margin-12.2%
Returns
ROE—
ROA-28.8%
ROIC (approx.)—
Asset turnover1.10x
Leverage & solvency
Liabilities / assets146.1%
Debt / equity—
Current ratio3.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.01x
Accruals ratio28.9%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $89.00M | $72.46M | $50.96M | $37.84M | $27.48M | $24.21M | $20.25M | $24.57M |
| Cost of revenue | $7.50M | $6.57M | $4.14M | $3.29M | $3.28M | $3.55M | $2.33M | $2.47M |
| Gross profit | $81.50M | $65.88M | $46.82M | $34.55M | $24.20M | $20.66M | $17.92M | $22.09M |
| R&D expense | $25.96M | $17.34M | $15.60M | $14.31M | $14.01M | $18.91M | $19.87M | $14.89M |
| SG&A expense | $47.21M | $48.44M | $51.49M | $39.35M | $37.58M | $43.20M | $34.97M | $34.86M |
| Operating income | $8.33M | $111,000 | -$20.26M | -$19.11M | -$27.39M | -$41.45M | -$36.91M | -$27.66M |
| Pretax income | -$446,000 | -$8.72M | -$28.35M | -$26.64M | -$34.40M | -$48.92M | -$43.45M | -$34.86M |
| Income tax | $1.02M | $5.63M | -$4.77M | -$275,000 | -$1.05M | $1.01M | $392,000 | $2.65M |
| Net income | -$1.46M | -$14.35M | -$23.57M | -$26.36M | -$33.35M | -$49.94M | -$43.84M | -$37.51M |
| EBITDA | $8.43M | $211,000 | -$20.19M | -$19.04M | -$27.29M | -$41.35M | -$36.84M | -$27.59M |
| EPS (basic) | -0.03 | -0.28 | -0.47 | — | -0.69 | -1.05 | -0.92 | -0.80 |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $85.56M | $79.13M | $109.97M | $110.75M | $90.04M | $92.90M | $104.03M | $171.99M |
| Short-term investments | $6.35M | $30.16M | $39.74M | $9.71M | $63.79M | $83.11M | $112.03M | $110.67M |
| Receivables | $117.28M | $88.76M | $55.41M | $33.08M | $19.70M | $19.65M | $19.64M | $20.30M |
| Inventory | $25.15M | $24.59M | $20.92M | $16.46M | $8.34M | $7.13M | $7.59M | $9.23M |
| Current assets | $251.90M | $235.43M | $237.46M | $186.02M | $168.55M | $196.87M | $237.18M | $276.13M |
| PP&E, net | $588,000 | $597,000 | $616,000 | $637,000 | $695,000 | $688,000 | $627,000 | $655,000 |
| Total assets | $271.87M | $252.59M | $253.69M | $200.46M | $185.05M | $208.72M | $247.62M | $285.71M |
| Current liabilities | $74.03M | $61.91M | $50.63M | $46.42M | $42.24M | $47.55M | $42.00M | $45.95M |
| Long-term debt | $189.35M | $188.73M | $189.53M | $122.21M | $122.11M | $122.51M | $122.11M | $121.73M |
| Total debt | $189.35M | $188.73M | $189.53M | $122.21M | $122.11M | $122.51M | $122.11M | $121.73M |
| Total liabilities | $397.09M | $384.99M | $377.94M | $305.93M | $300.45M | $302.09M | $294.08M | $294.51M |
| Shareholders' equity | -$125.22M | -$132.40M | -$124.25M | -$105.47M | -$115.41M | -$93.38M | -$46.46M | -$8.80M |
| Net debt | $103.79M | $109.60M | $79.56M | $11.46M | $32.07M | $29.60M | $18.07M | -$50.25M |
| Shares outstanding | 49.03M | 48.87M | 48.71M | 48.35M | 46.78M | 46.20M | 46.10M | 42.23M |
| Cash flow statement | ||||||||
| Operating cash flow | -$15.20M | -$33.01M | -$45.32M | -$38.33M | -$42.27M | -$39.83M | -$42.02M | -$13.62M |
| Capital expenditure | $72,000 | $60,000 | $54,000 | $17,000 | $87,000 | $141,000 | $44,000 | $115,000 |
| Free cash flow | -$15.27M | -$33.07M | -$45.37M | -$38.34M | -$42.36M | -$39.97M | -$42.07M | -$13.73M |
| Investing cash flow | $19.85M | $1.67M | -$20.69M | $27.72M | $31.40M | $28.41M | -$25.96M | $60.62M |
| Financing cash flow | $1.78M | $500,000 | $65.20M | $31.32M | $8.27M | $296,000 | $34,000 | $71,000 |
| Depreciation & amortization | $100,000 | $100,000 | $75,000 | $75,000 | $100,000 | $100,000 | $72,000 | $68,000 |
| Stock-based compensation | $6.25M | $5.33M | $4.63M | $3.13M | $3.03M | $2.73M | $3.07M | $3.30M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.